Of 18F MEL050 Using PET/CT in Metastatic Melanoma
The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F MEL050 for finding sites of melanoma.
Metastatic Melanoma
RADIATION: 18F MEL050
Safety of 18F MEL050 administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F MEL050 administration., Up to 28 days following 18F MEL050 administration (+/- 7 days)
Percentage of injected 18F MEL050 dose in organs of interest., 10, 30, 60 and 120 minutes post 18F MEL050 administration|Percentage of unmetabolized 18F MEL050 in plasma and urine after radiotracer administration., 60, 120 and 180 minutes post 18F MEL050 administration.|Absorbed organ doses and whole body dose expressed as milliSv/200MBq administered dose., 10, 30, 60 and 120 minutes post 18F MEL050 administration
The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F MEL050 for finding sites of melanoma.